Hope for the Future

Sheri Baker |

Wow, what a very interesting experience at the All-Virtual 62nd ASH Annual Meeting and Exposition (ASH).  The total number of ASH abstracts for 2020 was 4800, down from last year’s 6000.  There were 688 Myeloma Abstracts.  179 of them were oral abstracts, which are presented in 15-minute time slots.  There were 500 poster abstracts, which […]

Considerations Regarding Maintenance Therapy in Myeloma

Jim Omel |

There is no doubt that patients who continue maintenance Revlimid (lenalidomide) following autologous transplant do better than those who do not.  Dr. Phil McCarthy showed unequivocally in CALGB 100104 (Revlimid vs placebo) that progression free survival (PFS) and overall survival (OS) are longer for patients taking maintenance Revlimid.  Likewise, maintenance therapy extends PFS for patients […]